Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment

Abstract

Background Advances in curative treatment for breast, colorectal, NSCLC and prostate cancer have led to improvements in cancer survival. Cancer treatment and recovery time can vary depending on the recommended modalities and intensity of therapy. Our objective was to determine the current real world duration of curative treatments for the four common cancers. Methods A retrospective review was completed of patients referred to BC Cancer from 2010 to 2016, ≤ 65 years old, newly diagnosed with stage I-III breast, colorectal, NSCLC or prostate cancer who received curative intent treatment. Information was collected on baseline characteristics, date of diagnosis, surgery, type, duration and intent of both radiotherapy and chemotherapy. Results In total, 22,275 patients were included: 55.7% breast, 22.4% colorectal, 9.2% NSCLC, 12.7% prostate cancer. Stage I/II/III at diagnosis: breast 47.2/38.7/14.1%, colorectal 26.5/30.1/43.5%, NSCLC 46.5/18.1/35.4%, prostate 7.7/62.9/29.4%. Patients treated with definitive surgery only: breast 35.9%, colorectal 58%, NSCLC 52.2%, prostate 40.1%. The median duration of multimodality treatment was breast 24.6 weeks, colorectal 26.7 weeks, NSCLC 9.1 weeks, and prostate 6.0 weeks. Conclusions Approximately half of patients who undergo curative cancer treatment require definitive radiotherapy or multimodality treatment. The median duration of therapy for the most commonly treated cancers ranged from 6.0–26.7 weeks. Multimodality curative treatment can be prolonged for selected cancers when accounting for the duration of adjuvant chemotherapy and radiotherapy and recovery time between modalities.

Traction Radiculopathy After Surgery for Lumbar Spinal Metastasis: A Case Report

“…In Japan, where 29.0% of the population is over 65 years old, cancer is the leading cause of death, accounting for 26.5% of all deaths [4,5]. Recent advances in cancer treatment and other fields of medicine have improved the prognosis for cancer patients, and more and more patients are living with cancer for a long period [2,3]. The Japanese Orthopedic Association has even proposed the concept of "locomotive syndrome in cancer patients," and treating locomotor diseases in cancer patients is an urgent issue that orthopedic surgeons in Japan need to address [6].…”

“…For this reason, opportunities for treating metastatic spinal tumors are also increasing [2]. In particular, breast and prostate cancer have a long prognosis, and surgical treatment of spinal metastases is increasingly considered during treatment [2,3].…”

“…Recently, the opportunity for the treatment of metastatic spinal tumors has been increasing as the prognosis of cancer patients improved due to advances in cancer treatment [1][2][3]. Breast cancer and prostate cancer that are characteristic of a high frequency of bone metastasis have a good prognosis, and surgical treatment for spinal metastases is increasingly considered during treatment [2,3].…”

Turning a Curve: How People Use Everyday Resources to Negotiate Recovery From Cancer Treatment With Curative Intent

“…At the end of cancer treatment, challenging physical and psychosocial effects can linger (Wong et al, 2021).…”

“…While survival rates are difficult to predict (Maringe et al, 2020), the community of people living 5 years beyond diagnosis is expanding (Guzzinati et al, 2018; Miller et al, 2019). Many have been treated with curative intent, undergoing surgery and/or chemotherapy or radiotherapy with the intent of removing cancer from the body (Wong et al, 2021). Removing all detectable disease from the body is not a guarantee that cancer will not recur, but the possibility of a complete recovery is increasing for many patients.…”